Guanghai Dai

机构：Chinese PLA General Hospital · ORCID：0000-0002-7339-3840

发表论文 65 篇 · 总被引 2854 次 · h-index 19

代表论文

• Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial (2022 · Cancer Cell · 被引 579)
• Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study (2021 · 癌症：英文版 · 被引 207)
• Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) (2022 · Nature Communications · 被引 151)
• Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer (2021 · Journal of Immunology Research · 被引 60)
• Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China (2022 · Frontiers in Oncology · 被引 46)
• The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy (2021 · Frontiers in Oncology · 被引 27)